1 Min Read
* Mylan announces U.S. FDA approval of first generic for Copaxone® 40 mg/ml 3-times-a-week and may be eligible for 180-day exclusivity
* Mylan NV - co will begin shipping imminently Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.